Healthcare Supply Chain Playbook »

Newly published by Healthcare Packaging, this 40-page playbook discusses how to create the right global shipping strategies, based on interviews with leading experts in the field. Download your copy today. Learn more »

 
Article tools:
|
Bookmark and Share

FDA’s rising criticism: A response option

iStock_warning-and-risk.jpgWith an expanded staff and power, FDA 483 letters are expected to rise. Here’s one option on how to avoid and respond to agency criticism.

CEE Packaging, the Packaging Industry of Central and Eastern Europe, reports that a 10-step guide is available to help pharmaceutical processors, medical device manufacturers, and other life-sciences facilities respond appropriately within the permitted 15-day window of receiving a 483 letter from the agency. The guide, “How to Avoid and Respond to Public FDA Criticisms—Form 483 Letters—for Temperature, Humidity and other Controlled Environments,” comes from Veriteq.

CGMP.com provides some basics on FDA-issued warning letters.

Packaging World/Healthcare Packaging
legal columnist Eric Greenberg recently discussed the agency’s increasing activity. Read more about FDA, regulatory, and legal developments.

-Jim Butschli, Editor

Liked this article? Start your subscription to Healthcare Packaging for FREE:

Sign up to receive the print magazine six times per year and the e-mail newsletter twice a month.

First Name:
Last Name:
 
Company:
Email Address:

 

* indicates a sponsored article that was submitted directly to this Web site by the supplier, and was not handled by the Healthcare Packaging editorial staff. Healthcare Packaging may share your contact information with our sponsors, as detailed in our Privacy Policy. Healthcare Packaging will not share your information with a sponsor whose content you have not reviewed.